Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 25, 2022

Primary Completion Date

March 30, 2023

Study Completion Date

March 30, 2023

Conditions
Non-Alcoholic Fatty Liver Disease
Interventions
DRUG

BAR502

"Single oral doses of BAR 502/placebo will be administered as film-coated tablets, in the morning of Day 1, with 240 mL of water, after an overnight fasting of at least 8 hours.~BAR 502 film-coated tablets are available at dose strengths of 10, 50 and 150 mg. A maximum of 4 dose levels are pre-planned (10 mg, 50 mg, 150 mg, 300 mg)."

DRUG

Placebo

Matching BAR 502 placebo film-coated tablets will be given to 2 out of 8 subjects in each cohort using the same regimen as outlined for the active study treatment

Trial Locations (1)

Unknown

BlueClinical Phase I, Porto

Sponsors
All Listed Sponsors
lead

BAR Pharmaceuticals s.r.l.

NETWORK